Preston E. Bratcher

1.7k total citations · 1 hit paper
33 papers, 1.2k citations indexed

About

Preston E. Bratcher is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Preston E. Bratcher has authored 33 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 9 papers in Physiology and 8 papers in Epidemiology. Recurrent topics in Preston E. Bratcher's work include Cystic Fibrosis Research Advances (16 papers), Neonatal Respiratory Health Research (14 papers) and Asthma and respiratory diseases (8 papers). Preston E. Bratcher is often cited by papers focused on Cystic Fibrosis Research Advances (16 papers), Neonatal Respiratory Health Research (14 papers) and Asthma and respiratory diseases (8 papers). Preston E. Bratcher collaborates with scholars based in United States, United Kingdom and Netherlands. Preston E. Bratcher's co-authors include Amit Gaggar, Moon H. Nahm, J. Edwin Blalock, Tomasz Szul, Xin Xu, Rabindra Tirouvanziam, Ciarán A. Shaughnessy, Pamela L. Zeitlin, J. Michael Wells and Tarek Abdalla and has published in prestigious journals such as Cell, Nature Communications and PLoS ONE.

In The Last Decade

Preston E. Bratcher

31 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung

2019 336 citations Kristopher R. Genschmer, Derek W. Russell et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Preston E. Bratcher United States	17	561	462	236	196	155	33	1.2k
James Devaney Ireland	17	650 1.2×	363 0.8×	92 0.4×	263 1.3×	138 0.9×	27	1.2k
Camilla Margaroli United States	15	443 0.8×	358 0.8×	89 0.4×	277 1.4×	110 0.7×	41	911
Stephen E. Bottoms United Kingdom	13	391 0.7×	268 0.6×	96 0.4×	220 1.1×	59 0.4×	14	964
Gimano D. Amatngalim Netherlands	14	326 0.6×	299 0.6×	83 0.4×	161 0.8×	36 0.2×	24	981
Lihong Yao China	19	209 0.4×	326 0.7×	163 0.7×	210 1.1×	74 0.5×	83	977
Markus Weckmann Germany	18	345 0.6×	182 0.4×	155 0.7×	272 1.4×	81 0.5×	39	874
Koa Hosoki United States	20	204 0.4×	362 0.8×	109 0.5×	284 1.4×	66 0.4×	50	1.1k
Hajime Ishinaga Japan	18	162 0.3×	298 0.6×	80 0.3×	192 1.0×	205 1.3×	75	1.0k
Mojtaba Abdul Roda United States	10	256 0.5×	348 0.8×	52 0.2×	211 1.1×	167 1.1×	13	777
Steven E. Wilcoxen United States	17	404 0.7×	195 0.4×	193 0.8×	304 1.6×	37 0.2×	21	930

Countries citing papers authored by Preston E. Bratcher

Since Specialization

Citations

This map shows the geographic impact of Preston E. Bratcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Preston E. Bratcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Preston E. Bratcher more than expected).

Fields of papers citing papers by Preston E. Bratcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Preston E. Bratcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Preston E. Bratcher. The network helps show where Preston E. Bratcher may publish in the future.

Co-authorship network of co-authors of Preston E. Bratcher

This figure shows the co-authorship network connecting the top 25 collaborators of Preston E. Bratcher. A scholar is included among the top collaborators of Preston E. Bratcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Preston E. Bratcher. Preston E. Bratcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sagel, Scott D., Brandie D. Wagner, Jing Xie, et al.. (2025). Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Annals of the American Thoracic Society. 23(2). 241–251.

Veress, Livia A., et al.. (2023). Mesna Improves Outcomes of Sulfur Mustard Inhalation Toxicity in an Acute Rat Model. Journal of Pharmacology and Experimental Therapeutics. 388(2). 576–585. 3 indexed citations

Bratcher, Preston E., et al.. (2022). Acute vaping in a golden Syrian hamster causes inflammatory response transcriptomic changes. American Journal of Physiology-Lung Cellular and Molecular Physiology. 323(5). L525–L535. 3 indexed citations

Kotas, Maya E., Camille M. Moore, José Gurrola, et al.. (2022). IL-13–programmed airway tuft cells produce PGE2, which promotes CFTR-dependent mucociliary function. JCI Insight. 7(13). 27 indexed citations

Shaughnessy, Ciarán A., Pamela L. Zeitlin, & Preston E. Bratcher. (2022). Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. Journal of Cystic Fibrosis. 21(4). 637–643. 4 indexed citations

Shaughnessy, Ciarán A., Pamela L. Zeitlin, & Preston E. Bratcher. (2021). Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Scientific Reports. 11(1). 19810–19810. 51 indexed citations

Zeitlin, Pamela L., et al.. (2021). Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure. Scientific Reports. 11(1). 22616–22616. 2 indexed citations

Bratcher, Preston E. & Pamela L. Zeitlin. (2021). Expanding CFTR Modulator Testing to Carriers of CFTR Variants. Annals of the American Thoracic Society. 18(11). 1776–1779.

Goldfarbmuren, Katherine C., Nathan D. Jackson, Satria P. Sajuthi, et al.. (2020). Dissecting the cellular specificity of smoking effects and reconstructing lineages in the human airway epithelium. Nature Communications. 11(1). 2485–2485. 129 indexed citations

10.

Veress, Livia A., Preston E. Bratcher, Poojya Anantharam, et al.. (2020). Alleviation of methyl isocyanate−induced airway obstruction and mortality by tissue plasminogen activator. Annals of the New York Academy of Sciences. 1479(1). 134–147. 2 indexed citations

11.

Roda, Mojtaba Abdul, Xin Xu, Tarek Abdalla, et al.. (2019). Proline-Glycine-Proline Peptides are Critical in the Development of Smoke-induced Emphysema. American Journal of Respiratory Cell and Molecular Biology. 61(5). 560–566. 18 indexed citations

12.

Genschmer, Kristopher R., Derek W. Russell, Charitharth Vivek Lal, et al.. (2019). Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung. Cell. 176(1-2). 113–126.e15. 336 indexed citations breakdown →

13.

Day, Brian J., Preston E. Bratcher, Joshua D. Chandler, et al.. (2019). The thiocyanate analog selenocyanate is a more potent antimicrobial pro-drug that also is selectively detoxified by the host. Free Radical Biology and Medicine. 146. 324–332. 16 indexed citations

14.

Chioccioli, Maurizio, Luigi Feriani, Jurij Kotar, Preston E. Bratcher, & Pietro Cicuta. (2019). Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells. Nature Communications. 10(1). 1763–1763. 30 indexed citations

15.

Russell, Derek W., Kristopher R. Genschmer, Tomasz Szul, et al.. (2019). Benzyloxycarbonyl-proline-prolinal (ZPP): Dual complementary roles for neutrophil inhibition. Biochemical and Biophysical Research Communications. 517(4). 691–696. 2 indexed citations

16.

Pohl, Kerstin, David P. Nichols, Jennifer L. Taylor‐Cousar, et al.. (2018). Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS ONE. 13(12). e0209026–e0209026. 7 indexed citations

17.

Xu, Xin, Tarek Abdalla, Preston E. Bratcher, et al.. (2017). Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. European Respiratory Journal. 49(4). 1601102–1601102. 37 indexed citations

18.

Szul, Tomasz, Preston E. Bratcher, Kyle Fraser, et al.. (2015). Toll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release from Airway Epithelia via Exosomes. American Journal of Respiratory Cell and Molecular Biology. 54(3). 359–369. 55 indexed citations

19.

Bratcher, Preston E., Steven M. Rowe, Tomasz Szul, et al.. (2015). Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor. Journal of Cystic Fibrosis. 15(1). 67–73. 37 indexed citations

20.

Rotman, Ella, Preston E. Bratcher, & Andrei Kuzminov. (2009). Reduced lipopolysaccharide phosphorylation in Escherichia coli lowers the elevated ori/ter ratio in seqA mutants. Molecular Microbiology. 72(5). 1273–1292. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact